SpaceOAR hydrogel is used to reduce common side effects that men experience after receiving prostate cancer radiotherapy. In addition to the new payers, SpaceOAR is reimbursed by six out of seven ...

BEDFORD, Mass.--(BUSINESS WIRE)-- Augmenix, Inc. is pleased to announce that the company’s leading product, SpaceOAR hydrogel, is now available to millions of American men covered under Medicare, ...

“Our phase 3 clinical trial previously demonstrated that SpaceOAR offers a significant benefit in reducing the risk of rectal complications and damage associated with radiation therapy in the ...

Results published in the International Journal of Radiation Oncology Biology and Physics show on average no long-term declines in bowel and urinary quality of life for patients and 78% reduction in ...

WALTHAM, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced FDA ...

Dr. Varun Sundaram of Urology Austin spoke with Studio 512 Co-Host Rosie Newberry about prostate cancer, what you can do if you have been diagnosed, as well as treatments including “SpaceOAR™ Hydrogel ...

Dr. Varun Sundaram, a urologist at Urology Austin, joined Studio 512 Co-Host Rosie Newberry to talk about SpaceOAR Hydrogel and Rezūm Water Vapor Therapy. “The two treatments we commonly use are ...

A new device that has just been cleared for commercial use by the US Food and Drug Administration (FDA) offers men with prostate cancer who are undergoing radiotherapy (RT) some protection from ...

We read with great interest the article by Wong CH et al. [1]. “Does biodegradable peri-rectal spacer mitigate treatment toxicities in radiation therapy for localized prostate cancer—A systematic ...

Simon Stevens, the chief executive of NHS England, said: "This further advance in NHS care for prostate cancer means patients will have safer treatment with fewer side effects. "It's another step ...

According to the American Cancer Society (ACS), prostate cancer is the second most common cancer in American men and the second-leading cause of cancer-related death in the U.S. More than 164,000 new ...